1. 321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities. (18th September 2019) Authors: Poveda, A; Sackeyfio, A; Friedlander, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0259 Respiratory symptoms in primary sjÖgren's syndrome, a cross-sectional study of the oasis cohort. (15th June 2017) Authors: Dumusc, A; Fisher, B; Barone, F; Richards, A; Poveda, A; Higham, J; Rauz, S; Bowman, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗